Skip to main content
SNY
NASDAQ Life Sciences

Sanofi's Efdoralprin Alfa Outperforms Standard Therapy in Phase 2 AATD Trial

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$43.435
Mkt Cap
$103.501B
52W Low
$42.325
52W High
$53.36
52W Position info
2.6% above low
Off High info
19% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

SNY is trading near its 52-week low of $42.325 (2.6% above the low).

Summary

Sanofi announced highly positive Phase 2 results for its investigational drug, efdoralprin alfa, in treating Alpha-1 Antitrypsin Deficiency (AATD). The data demonstrated superiority over standard-of-care augmentation therapy, achieving significantly higher functional AAT (fAAT) levels and meeting both the primary and all key secondary endpoints with high statistical significance (p<0.0001). This is a material pipeline advancement, indicating efdoralprin alfa's potential to offer a superior treatment option with less frequent dosing for patients with this rare genetic condition. The strong efficacy and favorable safety profile could position the drug as a future standard of care, positively impacting Sanofi's long-term growth prospects. Investors will now focus on the progression to Phase 3 trials and subsequent regulatory submissions.

At the time of this announcement, SNY was trading at $43.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $103.5B. The 52-week trading range was $42.33 to $53.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SNY - Latest Insights

SNY
Oct 30, 2026, 3:54 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $43.03
Real-time Price: $48.19 info
Change: +$5.16 (+12%) info
Market Cap: $115.801B info
SNY
Oct 01, 2026, 5:22 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $41.31
Real-time Price: $48.19 info
Change: +$6.88 (+17%) info
Market Cap: $115.801B info
SNY
Sep 17, 2026, 6:09 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $42.71
Real-time Price: $48.19 info
Change: +$5.48 (+13%) info
Market Cap: $115.801B info
SNY
Aug 06, 2026, 6:02 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $43.26
Real-time Price: $48.19 info
Change: +$4.93 (+11%) info
Market Cap: $115.801B info
SNY
Jul 30, 2026, 7:34 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $43.66
Real-time Price: $48.19 info
Change: +$4.53 (+10%) info
Market Cap: $115.801B info